Entry |
|
Name |
Letolizumab (USAN/INN) |
Formula |
C1734H2688N466O538S10
|
Exact mass |
38967.4509
|
Mol weight |
38991.3459
|
Sequence |
EVQLLESGGG LVQPGGSLRL SCAASGFTFN WELMGWARQA PGKGLEWVSG IEGPGDVTYY ADSVKGRFTI SRDNSKNTLY LQMNSLRAED TAVYYCVKVG KDAKSDYRGQ GTLVTVSSAS TEPKSSDKTH TSPPSPAPEL LGGSSVFLFP PKPKDTLMIS RTPEVTCVVV DVSHEDPEVK FNWYVDGVEV HNAKTKPREE QYNSTYRVVS VLTVLHQDWL NGKEYKCKVS NKALPAPIEK TISKAKGQPR EPQVYTLPPS RDELTKNQVS LTCLVKGFYP SDIAVEWESN GQPENNYKTT PPVLDSDGSF FLYSKLTVDK SRWQQGNVFS CSVMHEALHN HYTQKSLSLS PGK (Disulfide bridge: 22-96, 167-227, 273-331) |
Type |
Peptide |
Efficacy |
Anti-inflammatory, Anti-CD154 antibody |
Type |
Monoclonal antibody |
Comment |
Treatment of inflammatory disease
|
Target |
|
Pathway |
hsa04060 | Cytokine-cytokine receptor interaction |
hsa04660 | T cell receptor signaling pathway |
|
Brite |
Target-based classification of drugs [BR:br08310]
Cytokines and receptors
Cytokines
Tumor necrosis factors
TNFSF5 (CD154)
D11122 Letolizumab (USAN/INN)
|
Other DBs |
|